10 completed, 1 terminated. 10 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 9, Terminated 1 |
| Phase 1 | 2 | Completed 2 |
Follow iscalimab: new trials by email Literature Review of iscalimab trials Research Report on iscalimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Safety and Tolerability of CFZ533 in Patients With Sjögren's Syndrome Iscalimab, Placebo - Sjogren's Syndrome | Phase 2 | Completed | Novartis Pharmaceuticals | 206 | 2021-01-05 | 2025-10-16 |
| Study of Safety and Efficacy of CFZ533 in Type 1 Diabetes Pediatric and Young Adult Subjects CFZ533, Placebo - Type 1 Diabetes Mellitus | Phase 2 | Completed | Novartis Pharmaceuticals | 44 | 2019-11-08 | 2025-04-08 |
| Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term Extension CFZ533, Tacrolimus - MMF - corticosteroids - Liver Transplant Rejection | Phase 2 | Terminated | Novartis Pharmaceuticals | 129 | 2019-10-07 | 2025-05-16 |
| Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's Syndrome CFZ533, Placebo - Sjögren Syndrome | Phase 2 | Completed | Novartis Pharmaceuticals | 273 | 2019-10-01 | 2026-05-18 |
| Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa CFZ533, Placebo to CFZ533, LYS006 - Hidradenitis Suppurativa | Phase 2 | Completed | Novartis Pharmaceuticals | 248 | 2019-02-27 | 2026-10-16 |
| Study the Efficacy and Safety of VAY736 and CFZ533 in SLE Patients VAY736, VAY736 Placebo, CFZ533 - Systemic Lupus Erythematosus (SLE) | Phase 2 | Completed | Novartis Pharmaceuticals | 107 | 2018-12-19 | 2026-05-14 |
| Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Lupus Nephritis. CFZ533, Placebo - Lupus Nephritis | Phase 2 | Completed | Novartis Pharmaceuticals | 57 | 2018-09-12 | 2024-10-09 |
| A Study to Evaluate the Safety and Effect of CFZ533 on Patients With Graves' Disease CFZ533 - Graves' Disease | Phase 2 | Completed | Novartis Pharmaceuticals | 15 | 2016-04-19 | 2021-01-05 |
| Safety,Tolerability,Pharmacokinetics and Efficacy of CFZ533 in Moderate to Severe Myasthenia Gravis Placebo, CFZ533 - Myasthenia Gravis, Generalized | Phase 2 | Completed | Novartis Pharmaceuticals | 44 | 2015-09-29 | 2021-01-05 |
| CCFZ533X2201 - PoC Study in de Novo Renal Transplantation CFZ533, Tacrolimus (Tac), Mycophenolate mofetil (MMF) - Kidney Transplantation | Phase 1 / Phase 2 | Completed | Novartis Pharmaceuticals | 59 | 2015-02-05 | 2021-09-28 |
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose CFZ533 in Rheumatoid Arthritis Patients CFZ533, Placebo - Rheumatoid Arthritis | Phase 1 | Completed | Novartis Pharmaceuticals | 75 | 2013-01-07 | 2020-12-11 |
Sjogren's Syndrome (2) · Arthritis, Rheumatoid (1) · Autoimmune Diseases (1) · Diabetes Mellitus, Type 1 (1) · Fatigue (1) · Graves Disease (1) · Hidradenitis Suppurativa (1) · Hyperthyroidism (1) · Lupus Erythematosus, Systemic (1) · Lupus Nephritis (1) · Myasthenia Gravis (1)
Germany (10) · United States (7) · Hungary (6) · Argentina (5) · France (5) · Netherlands (5) · Russia (5) · Italy (4) · South Korea (4) · Spain (4) · Taiwan (4) · Australia (3) · Austria (3) · Belgium (3) · Brazil (3)
PMID 31512728, PMID 31647605, PMID 34149627, PMID 39096929, PMID 40813108
2018 (4), 2015 (1)